Clinical Trials Logo
  1. Home
  2. Head & Neck Cancer
  3. NCT01268579

Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma

HEAD & NECK Cancer Clinical Trial

Official title:
A Pilot Study to Assess the Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma

Clinical Trial Summary

Human papillomavirus (HPV-16) is an important factor in the development of many tonsil and/or base of tongue squamous cell cancers. Although HPV-16 is not thought to cause cancer by itself, it appears to contribute to the development of tonsil and/or base of tongue cancer in many patients. It is likely that treatment for many patients with tonsil and/or base of tongue cancer could be improved if effective therapy to control HPV-16 is developed. The investigators in this study want to learn if ribavirin shows evidence of activity against HPV-16. Ribavirin is a pill therapy that is approved by the Food and Drug Administration (FDA) as part of the standard treatment for Hepatitis C. Laboratory experiments suggest that ribavirin might also be useful in the treatment of head and neck cancers. However, ribavirin has not yet been tested against head and neck cancer in patients. The purpose of this study is to find out the effects of ribavirin on tonsil and base tongue squamous cell cancer in patients. The main purpose of this study is to see if ribavirin changes the expression of certain proteins related to HPV infection in the tumor. The study will also find out if ribavirin changes how the tumor appears in a PET/CT scan (positron emission tomography/computed tomography scan).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01268579
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Completed
Phase N/A
Start date December 28, 2010
Completion date October 31, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT00670553 - A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer Phase 1
Completed NCT03799380 - DRIHNC - Dehydration Reduction in Head & Neck Cancer N/A
Completed NCT03157674 - Real-World Evidence and Treatment Patterns: Head and Neck Cancer
Completed NCT00565721 - A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Phase 2
Completed NCT00796952 - Muscle Composition and Function for Swallowing in Head/Neck Cancer Patients Phase 2
Completed NCT00935961 - RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer Phase 1
Recruiting NCT03065062 - Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Phase 1
Completed NCT03712397 - Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy Phase 2
Completed NCT04040166 - Carotid PET/MRI With DOTATATE in Patients Post Head and Neck Radiation Therapy N/A
Completed NCT00736619 - Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 1
Completed NCT02375958 - PCA062 in pCAD-positive Tumors. Phase 1